US FDA approves Asahi Kasei's drug for persistent herpes infections | Reuters

FDA approves Asahi Kasei drug for persistent herpes infections

The FDA approved Japan's Asahi Kasei's drug for treating persistent herpes simplex virus sores in immunocompromised patients who have not responded to available antiviral treatments.